Want to see TSE:VXL full AI Analyst Report?
VXL Stock Chart & Stats
C$0.13
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.13
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.13 - C$0.29
Previous CloseN/A
Volume4.43K
Average Volume (3M)1.45K
Market Cap
C$717.12K
Enterprise Value-C$33.38K
Total Cash (Recent Filing)C$671.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)1.4
Beta-1.00
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Equity BaseThe company's effectively no-debt position and increased equity in 2025 reduce financial distress risk and preserve strategic flexibility. Low leverage lowers mandatory financing costs, improves ability to pursue clinical programs or partnerships, and lengthens runway versus peers reliant on debt.
Reduced Cash Burn TrendOperating and free cash flow remain negative but materially smaller than prior years, indicating structurally lower cash consumption. A sustained reduction in burn rate eases near-term financing needs, improves chances to reach clinical inflection points before large dilution, and supports steadier program execution.
Focused Immunotherapy/T‑cell PlatformA platform centered on T‑cell immunotherapy in oncology and infectious disease aligns with durable industry demand and high unmet medical need. Platform-level science creates multi-indication optionality, enhances partnership and licensing potential, and can compound value if clinical validation occurs.
Bears Say
No Commercial RevenueAs a pre-commercial biotech with no product revenue and negative EBIT/EBITDA, Vaxil must rely on external funding or partnerships to continue operations. Lack of recurring commercial cash flow increases execution risk and makes long-term viability contingent on successful clinical outcomes or deal-making.
Persistent Negative Cash GenerationConsistent negative operating and free cash flow forces recurring capital raises or strategic transactions. Even with reduced burn, ongoing cash deficits constrain investment flexibility, heighten dilution risk for shareholders, and limit the company's ability to self-fund pivotal trials or commercialization activities.
Earnings Quality ConcernsA positive net income despite negative operating cash flow implies reliance on non‑operating items or accounting adjustments rather than core performance. This disconnect reduces the reliability of reported profits, complicates forecasting, and may weaken credibility with partners, lenders, and investors when assessing sustainable progress.
Vaxil Bio News
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was C$0.13 and its highest was C$0.29 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$717.12K.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Aug 31, 2026 which is in 61 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Currently, no data Available
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 3,984,021 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Defence Therapeutics
―